OCUL Earnings & Financial Statements
Ocular Therapeutix, Inc.
$7.20
-$0.04(-0.55%)
45
Overall
60
Value
27
Tech
50
Quality
Market Cap
$1.58B
Volume
2.20M
52W Range
$6.23 - $16.44
Target Price
$26.73
OCUL earnings and financial statements: Ocular Therapeutix, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
OCUL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M |
| Cost of revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M |
| Operating income | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M |
| EBITDA | -$246.38M | -$172.41M | -$60.31M | -$64.02M | $2.54M |
| Net income | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M |
| EPS (diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $808.06M | $457.94M | $252.06M | $149.29M | $204.89M |
| Total liabilities | $153.75M | $142.59M | $160.93M | $113.91M | $116.89M |
| Shareholders’ equity | $654.31M | $315.34M | $91.13M | $35.38M | $88.00M |
| Cash and equivalents | $737.06M | $392.10M | $195.81M | $102.30M | $164.16M |
| Long-term debt | $74.15M | $73.85M | $81.80M | $62.68M | $57.36M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$204.88M | -$134.68M | -$70.23M | -$59.60M | -$65.55M |
| Capital expenditure | -$11.88M | -$1.29M | -$6.09M | -$3.71M | -$1.19M |
| Free cash flow | -$216.89M | -$135.97M | -$76.32M | -$63.32M | -$66.74M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OCUL | $7.20 | -0.6% | 2.20M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ocular Therapeutix, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW